Fierce Pharma3d
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
Endpoints News3d
Paratek boosts com­mer­cial port­fo­lio in move to buy Opti­nose and its nasal spray
Paratek Pharmaceuticals to acquire Optinose and its nasal drug-device Xhance for up to $330M, expanding beyond antibiotics ...
Spring allergy season is around the corner. Here's what you can do to deal with congestion.
The start of spring kicks off a nasal nuisance for many people, but one drug meant to clear congestion has struggled to do ...
Healio5d
Chronic rhinosinusitis with nasal polyps improves with tezepelumab
Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...